Cited by 96RNA Interference and Gene DeliveryVirus-based gene therapy researchAnimal Genetics and Reproduction

Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector

Argyros, O, Wong, S P, Niceta, M, Waddington, S N, Howe, S J, Coutelle, C, Miller, A D, Harbottle, R P·2008·Gene Therapy

Abstract

An ideal gene therapy vector should enable persistent transgene expression without limitations of safety and reproducibility. Here we report the development of a non-viral episomal plasmid DNA (pDNA) vector that appears to fulfil these criteria. This pDNA vector combines a scaffold/matrix attachment region (S/MAR) with a human liver-specific promoter (alpha1-antitrypsin (AAT)) in such a way that long-term expression is enabled in murine liver following hydrodynamic injection. Long-term expression is demonstrated by monitoring the longitudinal luciferase expression profile for up to 6 months by means of in situ bioluminescent imaging. All relevant control pDNA constructs expressing luciferase are unable to sustain significant transgene expression beyond 1 week post-administration. We establish that this shutdown of expression is due to promoter methylation. In contrast, the S/MAR element appears to inhibit methylation of the AAT promoter thereby preventing transgene silencing. Although this vector appears to be maintained as an episome throughout, we have no evidence for its establishment as a replicating entity. We conclude that the combination of a mammalian, tissue-specific promoter with the S/MAR element is sufficient to drive long-term episomal pDNA expression of genes in vivo.

Integrity signals

Registry

Crossref · 10.1038/gt.2008.113

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The scaffold matrix attachment region (S/MAR)-containing sequence has been shown to maintain the plasmid in an episomal state and bind to nuclear scaffold proteins.

    “The scaffold matrix attachment region (S/MAR)-containing sequence has been shown to maintain the plasmid in an episomal state and bind to nuclear scaffold proteins [44].”

    From The Ocular Gene Delivery Landscape (2021) · cites this paper as [44]

The citation lists haven’t been fetched yet

References 49 · Cited by 96

Authors
Argyros, O., Wong, S. P., Niceta, M., Waddington, S. N., Howe, S. J., Coutelle, C., Miller, A. D., & Harbottle, R. P.
Affiliations
  • Imperial College London (GB)
  • The Royal Free Hospital (GB)
  • University College London (GB)
Corresponding author
Miller, A D
Venue
Gene Therapy
Published
2008-07-17
Volume
15
Issue
24
Pages
1593-1605
ISSN
  • 0969-7128 (ISSN-L)
  • 1476-5462
OpenAlex
W2040107868
Cited by
96
References
49
Citations by year
2026: 3 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 5 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 8 · 2014: 7 · 2013: 7 · 2012: 10
FWCI
3.97
Type
journal article
Language
en
Open access
closed
Locations
  • Gene Therapy (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Animal Genetics and Reproduction
Keywords
non-viral gene therapy, scaffold/matrix attachment regions, liver-specific promoter, hydrodynamic injection, persistent transgene expression, promoter methylation, transgene silencing, episome maintenance, luciferase expression, bioluminescence imaging
MeSH terms
alpha 1-Antitrypsin, Animals, Genetic Vectors, Hepatectomy, Humans, Immunohistochemistry, Injections, Liver, Luciferases, Mice, Inbred Strains, Plasmids, Promoter Regions, Genetic, Time Factors, Transfection, Genetic Therapy, Gene Expression, Transgenes, DNA Methylation, Matrix Attachment Regions, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review